MedTrace Logo

Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

NCT03899844 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1122

Last updated 2024-02-13

No results posted yet for this study

Summary

The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.

Conditions

  • Alzheimer Disease
  • Alzheimer Dementia

Interventions

OTHER

Blood collection, PiB PET/MRI, and cognitive testing

Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Randall Bateman, MD · Washington University School of Medicine

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2024-01-29
Completion
2024-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899844 on ClinicalTrials.gov